Dwayne Baxa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dwayne Baxa has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Lynne Shetron-Rama
2 shared publications- Alexandre Existe
Laboratoire National de Santé Publique, Port-au-Prince, Haïti
1 shared publication Alicia Golembieski
1 shared publicationAndrea Snow-Lampart
1 shared publicationAnne Kizy
1 shared publicationAshish D. Thekdi
1 shared publication
Latest Publications
- Open Access
- 5 June 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 237
Malaria elimination in Haiti by the year 2020: an achievable goal?
Haiti and the Dominican Republic, which share the island of Hispaniola, are the last locations in the Caribbean where malaria still persists. Malaria is an important public health concern in Haiti with 17,094 reported cases in 2014. Further, on January 12, 2010, a record earthquake devastated densely populated areas in Haiti including many healthcare and laboratory facilities. Weakened infrastructure provided fertile reservoirs for uncontrolled transmission of infectious pathogens. This situation results in unique challenges for malaria epidemiology and elimination efforts. To help Haiti achieve its malaria elimination goals by year 2020, the Laboratoire National de Santé Publique and Henry Ford Health System, in close collaboration with the Direction d’Épidémiologie, de Laboratoire et de Recherches and the Programme National de Contrôle de la Malaria, hosted a scientific meeting on “Elimination Strategies for Malaria in Haiti” on January 29-30, 2015 at the National Laboratory in Port-au-Prince, Haiti. The meeting brought together laboratory personnel, researchers, clinicians, academics, public health professionals, and other stakeholders to discuss main stakes and perspectives on malaria elimination. Several themes and recommendations emerged during discussions at this meeting. First, more information and research on malaria transmission in Haiti are needed including information from active surveillance of cases and vectors. Second, many healthcare personnel need additional training and critical resources on how to properly identify malaria cases so as to improve accurate and timely case reporting. Third, it is necessary to continue studies genotyping strains of Plasmodium falciparum in different sites with active transmission to evaluate for drug resistance and impacts on health. Fourth, elimination strategies outlined in this report will continue to incorporate use of primaquine in addition to chloroquine and active surveillance of cases. Elimination of malaria in Haiti will require collaborative multidisciplinary approaches, sound strategic planning, and strong ownership of strategies by the Haiti Ministère de la Santé Publique et de la Population.
- 5 June 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 237
Open AccessMalaria elimination in Haiti by the year 2020: an achievable goal?
Haiti and the Dominican Republic, which share the island of Hispaniola, are the last locations in the Caribbean where malaria still persists. Malaria is an important public health concern in Haiti with 17,094 reported cases in 2014. Further, on January 12, 2010, a record earthquake devastated densely populated areas in Haiti including many healthcare and laboratory facilities. Weakened infrastructure provided fertile reservoirs for uncontrolled transmission of infectious pathogens. This situation results in unique challenges for malaria epidemiology and elimination efforts. To help Haiti achieve its malaria elimination goals by year 2020, the Laboratoire National de Santé Publique and Henry Ford Health System, in close collaboration with the Direction d’Épidémiologie, de Laboratoire et de Recherches and the Programme National de Contrôle de la Malaria, hosted a scientific meeting on “Elimination Strategies for Malaria in Haiti” on January 29-30, 2015 at the National Laboratory in Port-au-Prince, Haiti. The meeting brought together laboratory personnel, researchers, clinicians, academics, public health professionals, and other stakeholders to discuss main stakes and perspectives on malaria elimination. Several themes and recommendations emerged during discussions at this meeting. First, more information and research on malaria transmission in Haiti are needed including information from active surveillance of cases and vectors. Second, many healthcare personnel need additional training and critical resources on how to properly identify malaria cases so as to improve accurate and timely case reporting. Third, it is necessary to continue studies genotyping strains of Plasmodium falciparum in different sites with active transmission to evaluate for drug resistance and impacts on health. Fourth, elimination strategies outlined in this report will continue to incorporate use of primaquine in addition to chloroquine and active surveillance of cases. Elimination of malaria in Haiti will require collaborative multidisciplinary approaches, sound strategic planning, and strong ownership of strategies by the Haiti Ministère de la Santé Publique et de la Population.
- 1 October 2014
- Vol. 61 (4) , 281-7
Hypothesis: Can clofazimine prevent IRIS in HIV/TB co-infected individuals?
- 1 October 2014
- Vol. 61 (4) , 281-7
Hypothesis: Can clofazimine prevent IRIS in HIV/TB co-infected individuals?
- 1 February 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 58 (2) , 212-216
Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States
- 1 February 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 58 (2) , 212-216
Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States
- 21 December 2012
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 15 (1) , 52-60
HCV Enters the Twenty-First Century
Almost one-third of Americans infected with human immunodeficiency virus (HIV) and 7 million worldwide are coinfected with hepatitis C virus (HCV). The principal route of HCV spread in the US is injection drug use but there are recent reports of outbreaks of acute HCV infection among HIV-infected men who have sex with men. With increased survival as a result of highly active antiretroviral therapy, HCV-associated liver disease has become a leading cause of death in HIV-infected individuals. Currently, telaprevir and boceprevir, both NS3/NS4A inhibitors that significantly improve sustained response when added to pegylated interferon and ribavirin, are approved only for HCV monoinfection. The optimal combination of agents, therapy durations and the timing of treatment remain major challenges in coinfected patients.
- 21 December 2012
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 15 (1) , 52-60
HCV Enters the Twenty-First Century
Almost one-third of Americans infected with human immunodeficiency virus (HIV) and 7 million worldwide are coinfected with hepatitis C virus (HCV). The principal route of HCV spread in the US is injection drug use but there are recent reports of outbreaks of acute HCV infection among HIV-infected men who have sex with men. With increased survival as a result of highly active antiretroviral therapy, HCV-associated liver disease has become a leading cause of death in HIV-infected individuals. Currently, telaprevir and boceprevir, both NS3/NS4A inhibitors that significantly improve sustained response when added to pegylated interferon and ribavirin, are approved only for HCV monoinfection. The optimal combination of agents, therapy durations and the timing of treatment remain major challenges in coinfected patients.
- 1 August 2011
- Published by Elsevier in American Journal of Infection Control
- Vol. 39 (6) , 483-487
In vitro evaluation of a novel process for reducing bacterial contamination of environmental surfaces
- 1 August 2011
- Published by Elsevier in American Journal of Infection Control
- Vol. 39 (6) , 483-487
In vitro evaluation of a novel process for reducing bacterial contamination of environmental surfaces